Citigroup Reinstates Buy on Sensei Biotherapeutics, Announces $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Samantha Semenkow has reinstated a Buy rating on Sensei Biotherapeutics (NASDAQ:SNSE) and announced a price target of $4.
June 03, 2024 | 7:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst Samantha Semenkow has reinstated a Buy rating on Sensei Biotherapeutics (NASDAQ:SNSE) and set a price target of $4.
The reinstatement of a Buy rating and the announcement of a $4 price target by a major financial institution like Citigroup is likely to positively impact the stock price of Sensei Biotherapeutics in the short term. This indicates confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100